Topical corticosteroids in allergic rhinitis; effects on nasal inflammatory cells and nasal mucosa

Clinical and Experimental Allergy

Volumn 31, Issue 4, 2001, Pages 529-535

  Holm, A F ^a   Fokkens, W J ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CD3 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEUKOTRIENE C4; LEUKOTRIENE D4; MESSENGER RNA; PLACEBO; PROSTAGLANDIN D2; RANTES; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN PRESENTING CELL; AUTOREGULATION; CELL INFILTRATION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; EPISTAXIS; HUMAN; IMMUNOPHARMACOLOGY; INFLAMMATORY CELL; LYMPHOCYTE COUNT; MAST CELL; NEUTROPHIL CHEMOTAXIS; NOSE MUCOSA; PATHOGENESIS; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SEASONAL VARIATION; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; NASAL MUCOSA; RHINITIS, ALLERGIC, PERENNIAL;

EID: 0035725336     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01091.x     Document Type: Review

References (64)

1. Human eosinophils
2. Interleukin-5 preferentially recruits eosinophils from vessels in nasal mucosa
3. The Langerhans cell: An underestimated cell in atopic disease
4. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: Relationship to tissue eosinophilia
5. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils
6. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis
7. T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis
8. Interleuldn-8 (IL-8): The major neutrophil chemotactic factor in the lung
9. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3
10. Modulation of eosinophil chemotaxis by interleukin-5
11. RANTES is a chemotactic and activating factor for human eosinophils
12. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
13. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy
14. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials
15. Systemic corticosteroid treatment for seasonal allergic rhinitis: A common but poorly documented therapy
16. Rhinitis
17. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis
18. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology
19. Dose tolerance study of fiuticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis
20. Onset of action of mometasoue furoate nasal spray (NASONEX) in seasonal allergic rhinitis
21. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: A placebo-oontrolled, double-blind study
22. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: A safety and biopsy study
23. Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): Can it be achieved?
24. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration
25. Consensus statement on the treatment of allergic rhinitis
26. Prevention of pollen rhinitis symptoms: Comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study
27. Topical glucocorticosteroids and allergen-induced increase in nasal reactivity: Relationship between treatment time and inhibitory effect
28. Basophil influx occurs after nasal antigen challenge: Effects of topical corticosteroid pretreatment
29. Proteinase content of mast cells of nasal mucosa; effects of natural allergen exposure and of local corticosteroid treatment
30. Early and late nasal symptom response to allergen challenge. The effect of pretreatment with a giueocorticosteroid spray
31. Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa; effects of a single allergen challenge
32. Long-term safety of budesonide nasal aerosol: A 5.5-year follow-up study
33. Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: A review of five years' experience
34. Beclomethasone dipropionate aerosol and nasal mucosa
35. Intranasal fluocortin butyl in patients with perennial rhinitis: A 12-month efficacy and safety study including nasal biopsy
36. Glucocorticosteroids and rhinitis
37. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids
38. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesohide in children
39. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray
40. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate
41. Inhaled and intranasal steroids: The differences explained in terms of potential for growth effects
42. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: A dose response study
43. Fluticasone propionate aqueous nasal spray: A well-tolerated and effective treatment for children with perennial rhinitis
44. Inhaled and nasal corticosteroids: Safety aspects
45. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: A biopsy and brush study
46. Effect of 3 months' nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis
47. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge
48. Topical glucocorticoids inhibit activation by allergen in the upper respiratory tract
49. Role of mast cells and basophils in rhinitis
50. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: A biopsy study
51. Cytokine immunoreactivity in seasonal rhinitis: Regulation by a topical corticosteroid
52. The effect of fluticasone propionate aqueous nasal spray on nasal mucosal inflammation in perennial allergic rhinitis
53. Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis
54. A double-blind comparison of two different dosages of Fluticasone Propionate Aqueous Nasal Spray in the treatment of patients with perennial allergic rhinitis: A biopsy study
55. Macrophages on the nasal mucosal surface in provoked and naturally occurring allergic rhinitis
56. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: Downregulation by inhaled corticosteroids
57. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: Effect of the glucocorticoid budesonide
58. Allergic rhinitis and inflammation: The effect of nasal corticosteroid therapy
59. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis
60. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids
61. Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids
62. The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis